hengrui glp-1 In a Phase 3 program reported by Kailera Therapeutics and partner Jiangsu Hengrui, two China trials of the oral small-molecule receptor agonist HRS-7535 met their primary goals in obesity and in Media Centre | EASD
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3



























